Benefits from immunization during the vaccines for children program era — United States, 1994-2013

Morbidity and Mortality Weekly Report

Volumn , Issue 16, 2014, Pages 352-355

  Whitney, Cynthia G ^a   Zhou, Fangjun ^a   Singleton, James ^a   Schuchat, Anne ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CHILD HEALTH CARE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; INFANT; INFECTION CONTROL; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PROGRAM EVALUATION; UNITED STATES; UTILIZATION REVIEW;

CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; PROGRAM EVALUATION; UNITED STATES;

EID: 84899031200     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Omnibus Budget Reconciliation Act of 1993. Subtitle D—Group Health Plans. Pages 326-34. Available at http://www.gpo.gov/fdsys/pkg/BILLS-103hr2264enr/pdf/BILLS-103hr2264enr.pdf.
2. Orenstein WA. The role of measles elimination in development of a national immunization program. Pediatr Infect Dis J 2006;25:1093-101.
3. Hinman AR, Orenstein WA, Schuchat A. Vaccine-preventable diseases, immunizations, and MMWR—1961-2011. In: Public health then and now: celebrating 50 years of MMWR at CDC. MMWR 2011(Suppl No. 4);60:49-57.
4. CDC. National, state, and local area vaccination coverage among children aged 19-35 months—United States, 2012. MMWR 2013;62:733-40.
5. Zhou F, Shefer A, Wenger J, et al. Economic evaluation of the routine childhood immunization program in the U.S., 2009. Pediatrics 2014;133:577-85.
6. Kostova D, Reed C, Finelli L, et al. Influenza illness and hospitalizations averted by influenza vaccination in the United States, 2005-2011. PLoS One 2013;8:e66312.
7. Van Panhuis WG, Grefenstette J, Jung SY, et al. Contagious diseases in the United States from 1888 to the present. N Engl J Med 2013;369:2152-8.
8. Roush SW, Murphy TV, Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccinepreventable diseases in the United States. JAMA 2007;298:2155-63.
9. Ray GT, Pelton SI, Klugman KP, Strutton DR, Moore MR. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009;27:6483-94.
10. National Vaccine Advisory Committee. Protecting the public’s health: critical functions of the Section 317 immunization program—a report of the National Vaccine Advisory Committee. Public Health Rep 2013;128:78-95.